CD274 and neoplasm: Likewise, in mice bearing CT26, tumor regression was observed in 25% of test animals with PD-1 blockade, 50% with CTLA-4 blockade, and 33% with PD-L1 blockade, as compared to 75% (p < 0.01 for the combination to checkpoint inhibitor monotherapy comparison) with combined CTLA-4 plus PD-1 or PD-L1 blockade.